Investors
Since 2003, Nujira has benefited from the backing of Amadeus Capital, 3i and Cambridge Gateway Fund.
Amadeus was founded to invest in new technologies in the UK and continental Europe, and now manages three funds totalling £285 million. The founders and directors have over 60 years' experience in starting up, financing and growing technology companies.
Amadeus is supported by an Advisory Board comprising of top executives from institutional and corporate investors and experienced international venture capitalists drawing upon advice from a range of experts on technical and resourcing issues.
3i is a world leader in private equity and venture capital. We focus on Buyouts, Growth Capital and Venture Capital and invest across Europe, in the United States and in Asia. Our competitive advantage comes from our international network and the strength and breadth of our relationships in business. These underpin the value that we deliver to our portfolio and to our shareholders.
3i’s global venture capital team invest in scaleable early to late-stage fast growth technology and healthcare businesses across Europe, US, Asia and Israel. 3i VC plans to invest $1.5bn funds over the next five years in exciting and ambitious companies in three main areas: healthcare (medtech and biotech), consumer IT (Internet, telecoms, digital media and electronics) and the clean technology sector.
The Cambridge Gateway Fund is a Cambridge, UK-based venture capital fund specialising in investments in early stage companies.
From its base at the centre of one of the world's fastest growing technology clusters, Gateway commits capital across the UK, actively seeking exceptional companies with unique technology in the IT, communications and life science sectors. Gateway is also represented on the East Coast of the USA. The £35.3 million Fund is advised by Avlar BioVentures Ltd, which is authorised and regulated by the Financial Services Authority.